Current and future therapies for inflammatory bowel disease.
The introduction of biologic agents to the therapeutic arsenal has dramatically impacted the way we treat patients with inflammatory bowel disease, allowing clinicians to achieve lasting remission in patients who are unresponsive to conventional therapies. New research continues to expand our understanding of the inflammatory cascade of ulcerative colitis and Crohn's disease, revealing a host of potential therapeutic targets for intervention. As we look toward the future in this rapidly developing field, we must learn how best to incorporate these new agents into the treatment algorithm to enhance or replace conventional therapies.
Zisman
Timothy L
TL
Clinical Research Fellow in Gastroenterology, The University of Chicago Hospitals, 5841 S. Maryland Avenue MC 4076, Chicago, IL 60637, USA. timothy.zisman@uchospitals.edu
Kane
Sunanda V
SV
D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*
D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents